Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | ...

Eli Lilly has shared phase 1 data on an antibody-drug conjugate (ADC) in platinum-sensitive ovarian cancer (PSOC), shedding ...

Gilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, ...

Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) ...

Bolt Biotherapeutics is acquiring Prana Therapies in a stock-for-stock reverse merger aimed at advancing Prana’s pipeline of ...

Roche is paying Zymeworks $55 million upfront for ZW209, bagging global rights to a trispecific designed to improve on the ...

Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...

Georgiamune, an immunology-focused biotech out of Maryland, has licensed a preclinical cancer drug candidate to Menarini ...

Japan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially ...

Researchers are exploring a revolutionary way to predict a patient's response to immunotherapies by creating a tumor “avatar” ...